{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:54:16Z","timestamp":1792994056316,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Describe the effect of pegylation on asparaginase pharmacokinetics and immunogenicity.Identify the current pegaspargase indications.Discuss the advantages of pegaspargase treatment.Outline the clinical trial design leading to pegaspargase approval by the FDA.List the major adverse events associated with pegaspargase treatment.<\/jats:p>\n                  <jats:p>CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.12-8-991","type":"journal-article","created":{"date-parts":[[2007,8,31]],"date-time":"2007-08-31T18:04:06Z","timestamp":1188583446000},"page":"991-998","source":"Crossref","is-referenced-by-count":285,"title":["FDA Drug Approval Summary: Pegaspargase (Oncaspar\u00ae) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL)"],"prefix":"10.1093","volume":"12","author":[{"given":"Patricia Anne","family":"Dinndorf","sequence":"first","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gootenberg","sequence":"additional","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Keegan","sequence":"additional","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,8,1]]},"reference":[{"key":"2021122208425529800_R1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/1911114a0","article-title":"Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects","volume":"191","author":"Broome","year":"1961","journal-title":"Nature"},{"key":"2021122208425529800_R2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1097-0142(197002)25:2<306::AID-CNCR2820250206>3.0.CO;2-H","article-title":"E. coli L-asparaginase in treatment of leukemia and solid tumors in 131 children","volume":"25","author":"Tallal","year":"1970","journal-title":"Cancer"},{"key":"2021122208425529800_R3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mpo.2950030410","article-title":"Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia","volume":"3","author":"Jones","year":"1977","journal-title":"Med Pediatr Oncol"},{"key":"2021122208425529800_R4","first-page":"3893","article-title":"Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: A report from Children's Cancer Study Group","volume":"39","author":"Ertel","year":"1979","journal-title":"Cancer Res"},{"key":"2021122208425529800_R5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM198609113151101","article-title":"Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia","volume":"315","author":"Clavell","year":"1986","journal-title":"N Engl J Med"},{"key":"2021122208425529800_R6","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199506153322407","article-title":"Childhood leukemias","volume":"332","author":"Pui","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122208425529800_R7","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1592\/phco.23.9.3S.32886","article-title":"Pegylation: Engineering improved biopharmaceuticals for oncology","volume":"23","author":"Molineux","year":"2003","journal-title":"Pharmacotherapy"},{"key":"2021122208425529800_R8","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"2021122208425529800_R9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00043426-200203000-00004","article-title":"A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962)","volume":"24","author":"Kurre","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122208425529800_R10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32A","author":"Boos","year":"1996","journal-title":"Eur J Cancer"},{"key":"2021122208425529800_R11","first-page":"796","volume-title":"Cancer Medicine","author":"Capizzi","year":"1993","edition":"Third Edition"},{"key":"2021122208425529800_R12","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V96.5.1709","article-title":"Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group study","volume":"96","author":"Abshire","year":"2000","journal-title":"Blood"},{"key":"2021122208425529800_R13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","article-title":"Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia","volume":"96","author":"Ahlke","year":"1997","journal-title":"Br J Haematol"},{"key":"2021122208425529800_R14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2000.02187.x","article-title":"Pegylated asparaginase (Oncospar) in children with ALL: Drug monitoring in reinduction according to the ALL\/NHL-BFM 95 protocols","volume":"110","author":"M\u00fcller","year":"2000","journal-title":"Br J Haematol"},{"key":"2021122208425529800_R15","first-page":"4554","article-title":"L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi","year":"1981","journal-title":"Cancer Res"},{"key":"2021122208425529800_R16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clin Pharmacokinet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-8-991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-8-991","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/8\/991\/41835785\/oncolo_12_8_991.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/8\/991\/41835785\/oncolo_12_8_991.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:10:23Z","timestamp":1640185823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/8\/991\/6397139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2007,8,1]]},"published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-8-991","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,8,1]]},"published":{"date-parts":[[2007,8,1]]}}}